Beiersdorf stock’s long slump has finally been enough to make one major broker step back from its bearish stance.
UBS upgraded the German skincare and consumer-goods group to “neutral” from “sell” on Tuesday.
The analysts argued that after a two-year share-price slide, the valuation now looks far less demanding.
But the move was hardly a full-throated endorsement.
UBS also cut its 12-month price target to €80 from €90, leaving only modest upside from Beiersdorf’s March 30 close of €75.40.
It means UBS is no longer outright negative on the stock, but it is not ready to turn bullish either.
Beiersdorf stock: A valuation upgrade, not a recovery call
The timing reflects how hard the stock has been hit.
According to UBS, Beiersdorf shares are down about 20% since the start of 2026, compared with a roughly 7% decline for the broader sector.
Over the past 24 months, the stock has dropped around 44%, while the sector has been broadly flat.
UBS’s rating change is mainly about valuation rather than improving business momentum.
The broker said Beiersdorf stock now trades at about 17 times estimated 2026 earnings and roughly 7 times EV/EBITDA.
UBS sees this as around a 20% discount to the broader European Food, Household and Personal Care sector.
The figure is well below Beiersdorf’s own 10-year average price-to-earnings multiple of 27 times.
In simple terms, UBS is saying the stock has become cheap enough that maintaining a “sell” rating is harder to justify.
That distinction matters as a neutral rating is not a call that the business has turned a corner or that a strong rebound is imminent.
Operational worries persist
The reason UBS remains restrained is that the near-term operating picture still looks soft.
The bank cut its 2026 adjusted earnings-per-share forecast to €4.27 and its 2027 estimate to €4.21, both below consensus.
It also expects a weak first quarter, forecasting consumer organic sales down 4.8% and Tesa sales down 2.5%.
Within the consumer division, UBS sees La Prairie as the biggest drag, with sales expected to fall about 20%, while Nivea is forecast to post a 6% decline in organic sales.
Derma is the brighter spot, with expected growth of around 8% in the quarter.
That mix helps explain why the stock remains difficult to call.
Beiersdorf still has parts of the portfolio growing, but not enough to offset softness in key brands and geographies.
The company itself has already set a cautious tone for 2026.
Its financial calendar shows the next major checkpoint will come on April 21, when it publishes its quarterly statement for January through March.
What makes the Beiersdorf story more nuanced now is how much bad news the market appears to be pricing in.
The post Is Beiersdorf stock a buy after 44% crash? UBS upgrade offers key signals appeared first on Invezz
